Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies | Zendy

F. Huguet | Zendy; Thierry André | Zendy; Pascal Hammel | Zendy; Pascal Artru | Zendy; Jacques Balosso | Zendy; Frédèric Selle | Zendy; Élisabeth Deniaud-Alexandre | Zendy; Philippe Ruszniewski | Zendy; E. Touboul | Zendy; Roberto Labianca | Zendy; Aimery de Gramont | Zendy; Christophe Louvet | Zendy

Open Access

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

Author(s) -

F. Huguet,

Thierry André,

Pascal Hammel,

Pascal Artru,

Jacques Balosso,

Frédèric Selle,

Élisabeth Deniaud-Alexandre,

Philippe Ruszniewski,

E. Touboul,

Roberto Labianca,

Aimery de Gramont,

Christophe Louvet

Publication year - 2007

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2006.07.5663

Subject(s) - medicine , chemoradiotherapy , pancreatic cancer , chemotherapy , adenocarcinoma , surgery , cancer , gastroenterology

The management of locally advanced (LA) pancreatic cancer patients remains controversial. To select patients who could benefit from chemoradiotherapy (CRT), the therapeutic strategy used by the Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) consisted of initial chemotherapy (CT) for at least 3 months. The decision to administer CRT or continue CT in nonprogressive patients was the investigator's choice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research